Marc‐Andrea Baertsch

Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE

Hartmut Goldschmidt, Marc‐Andrea Baertsch, Jana Schlenzka et al. · Leukemia · 2020 · 67 citations

Medicine, Oncology, Pharmacotherapy +15

Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma

Marc‐Andrea Baertsch, K. Elias, Thomas Hielscher et al. · Blood Cancer Journal · 2021 · 33 citations · Full text

Medicine, Hematology, Pharmacotherapy +15

T cell-mediated curation and restructuring of tumor tissue coordinates an effective immune response

John W. Hickey, Maximillian Haist, Nina B. Horowitz et al. · Cell Reports · 2023 · 32 citations · Full text

Medicine, Immunology, Oncology +17

Bone marrow breakout lesions act as key sites for tumor-immune cell diversification in multiple myeloma

Raphael Lutz, Alexandra M. Poos, Llorenç Solé‐Boldo et al. · Science Immunology · 2025 · 21 citations

Life Sciences, Immunology, Oncology +17

Cyclophosphamide‐based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase <scp>III</scp> trial Re<scp>LA</scp>psE

Marc‐Andrea Baertsch, Jana Schlenzka, Katharina Lisenko et al. · European Journal Of Haematology · 2017 · 20 citations

Medicine, Pharmacology, Pharmacotherapy +17